Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590513 | 1.00 | POLB (0.42) | POLBSLC6A9SMN1; SMN2GAAOPRM1 | |
| SCHEMBL19862623 | 0.98 | SMN1; SMN2 (0.40) | POLBSLC6A9SMN1; SMN2GAAOPRM1 | |
| SCHEMBL18590511 | 0.98 | SMN1; SMN2 (0.40) | POLBSLC6A9SMN1; SMN2GAAOPRM1 | |
| SCHEMBL19559433 | 0.84 | DDB1 (0.43) | SMN1; SMN2GAAAKR1B1KMT2ARAB9A | |
| SCHEMBL20041908 | 0.82 | DDB1 (0.44) | SMN1; SMN2GAAKMT2APDE7ANPC1 | |
| SCHEMBL19559384 | 0.82 | DDB1 (0.44) | SMN1; SMN2GAAKMT2APDE7ANPC1 | |
| SCHEMBL19862624 | 0.77 | SMN1; SMN2 (0.43) | SMN1; SMN2GAAKMT2ASIRT1THRB | |
| SCHEMBL19862621 | 0.71 | POLB (0.41) | POLBSLC6A9SMN1; SMN2AKR1B1KMT2A | |
| SCHEMBL18590479 | 0.71 | POLB (0.41) | POLBSLC6A9SMN1; SMN2AKR1B1KMT2A | |
| SCHEMBL19095210 | 0.71 | SLC6A9 (0.37) | POLBSLC6A9OPRM1AKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029983-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | POLB 4654/4885SLC6A9 680/4885SMN1; SMN2 3809/4885 |
| US-20180044290-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | POLB 4654/4885SLC6A9 680/4885SMN1; SMN2 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.